Foreknow Biotech
Research Oriented Service as Core
Foreknow Biotech is a biotechnology development company founded in 2019. We develop independently or obtain new technologies through technology transfer authorization. Nowadays the main core of company business is molecular detection and artificial intelligence automatic detection and interpretation. The chairman Luo Zhengde is an alumnus of the National Defense Medical Center and has been engaged in medical industry and pharmaceutical industry. The company’s research and development technology is transferred from Chang Gung Medical College. The chief consultant Dr. Chen Zeqing, a Phd of Oxford University is well-known worldwide. The original shareholders of the company are from professional individuals of medical, pharmaceutical, electronic industry, patent and so on.
The main core of our company is molecular detection (IVD, LDT, RUO) together with the applications of artificial intelligence. In particular, master the technology of Fluorescent In Situ Hybridization (FISH), which applied in the companion diagnostics of precise cancer treatment and customized fluorescent probe design for various clinical diagnostic tests, animals, plants, microbes gene testing and automatic analysis of program development.
Academic Information
Fluorescence in situ hybridization (FISH) is a molecular cytogenetic technique that uses fluorescent probes that bind to only particular parts of a nucleic acid sequence with a high degree of sequence complementarity. It was developed by biomedical researchers in the early 1980s[1] to detect and localize the presence or absence of specific DNA sequences on chromosomes. Fluorescence microscopy can be used to find out where the fluorescent probe is bound to the chromosomes. FISH is often used for finding specific features in DNA for use in genetic counseling, medicine, and species identification.[2] FISH can also be used to detect and localize specific RNA targets (mRNA, lncRNA and miRNA)[citation needed] in cells, circulating tumor cells, and tissue samples. In this context, it can help define the spatial-temporal patterns of gene expression within cells and tissues.
Source: Wikipedia (https://en.wikipedia.org/wiki/Fluorescence_in_situ_hybridization)
Stable Coronary Artery Disease：calss IIa
For patients who make refractory angina ineffective, EECP should be considered to relieve symptoms in order to achieve the best medical treatment and blood circulation reconstruction strategy.
EECP is considered to reduce refractory angina in patients with stable ischemic heart disease: II b
FISH Fluorescent Probe
3F.-3, No. 293, Sec. 1, Beixin Rd., Xindian Dist., New Taipei City 231, Taiwan (R.O.C.)
1F.-2, No. 362, Sanmin Rd., Luzhou Dist., New Taipei City 247, Taiwan (R.O.C.)
No. 58-13, Pinghe, Huwei Township, Yunlin County 632, Taiwan (R.O.C.)
COPYRIGHT © 2023 Foreknow Biotech Ltd. ALL RIGHTS RESERVED.
Design: TemplateMo